Form 8-K Kymera Therapeutics, For: Oct 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- EverCommerce names Alex Goor as new CEO, founder steps down
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
November 1, 2024 5:59 AM EDTB.Riley analyst Kalpit Patel raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $41.00 (from $36.00) while maintaining a Neutral rating.
The analyst comments "Kymera Therapeutics (KYMRNeutral, $41 PT) announced 3Q24 earnings and provided a business update. Patient dosing has commenced for KT-621, the companys STAT6 degrader, with... More
